Transitional cell cancer
Drug research and approvals for transitional cell cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 151 studies of transitional cell cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 151
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerNCT07908979 · Phase 2 · Fox Chase Cancer Center · starts Oct 16, 2026
- Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin IdentificationNCT07888374 · Not reported · Ruijin Hospital · starts Apr 5, 2026
- BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing…NCT07869836 · Phase 3 · SystImmune Inc. · starts Nov 1, 2026
- Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)NCT07855926 · Not reported · LMU Klinikum · starts May 17, 2026
- Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder SamplesNCT07848854 · Phase 2 · Yunnan Cancer Hospital · starts Aug 1, 2026
- A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin…NCT07815665 · Phase 2 / Phase 3 · Summit Therapeutics · starts Sep 10, 2026
- Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or MetastaticNCT07807345 · Phase 1 · Sutro Biopharma, Inc. · starts Oct 19, 2026
- Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma…NCT07789119 · Not reported · M.D. Anderson Cancer Center · starts Sep 10, 2026
- Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial CancerNCT07756437 · Not reported · AZ Sint-Lucas Gent · starts Nov 7, 2025
Approved 7
- VinflunineTubulin inhibitor
- Enfortumab vedotinNectin-4 binding agent
- PembrolizumabProgrammed cell death protein 1 inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- AtezolizumabProgrammed cell death 1 ligand 1 inhibitor
- AvelumabProgrammed cell death 1 ligand 1 other
- ErdafitinibFibroblast growth factor receptor inhibitor
Phase 3 1
- MitomycinDNA inhibitor
Phase 2 6
- CabazitaxelTubulin inhibitor
- DocetaxelTubulin inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- OxaliplatinDNA inhibitor
- SapanisertibSerine/threonine-protein kinase mTOR inhibitor
- DactolisibSerine/threonine-protein kinase mTOR inhibitor
Phase 1 or earlier 1
- VofatamabFibroblast growth factor receptor 3 inhibitor
How its trials ended
611 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 171 whose ending is known, 22% met their primary endpoint, 15% missed it and 64% stopped early.
- Ongoing20734%
- Completed, result not reported15425%
- Status unknown7913%
- Stopped: other or unclear508%
- Met its primary endpoint376%
- Stopped: enrollment or feasibility274%
- Missed its primary endpoint254%
- Stopped: sponsor or business decision173%
- Stopped: lack of efficacy71%
- Stopped: funding61%
- Stopped: safety2<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA